Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Earnings Data
Report Date
Feb 19, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.61Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlights strong growth in the GBM segment and international markets, along with regulatory progress for new indications. However, these positives are tempered by challenges in the non-small cell lung cancer launch, flat growth in the U.S. market, and financial setbacks such as reduced gross margin and net loss.Company Guidance
GBM Patient Growth
The GBM business remains solid with active patients growing between 5% and 12% year-over-year for the last 9 consecutive quarters, ending Q3 2025 with 4,277 GBM patients on therapy.
International Expansion
Significant growth in international markets with France, Japan, and Germany contributing 27%, 8%, and 7% growth respectively. Positive national coverage decision from the Spanish Ministry of Health expected to mature over time.
Regulatory Progress in Japan
Received approval from Japanese regulators for the use of Optune Lua with checkpoint inhibitors in advanced or recurrent non-small cell lung cancer, anticipating strong physician adoption.
PANOVA-3 Progress
Substantial progress with PANOVA-3 data submitted to the FDA for pancreatic cancer treatment, with expected approval mid-next year.
Financial Performance
Net revenues of $167 million, an increase of 8% from the third quarter last year driven by strong performance in GBM franchises in France, Germany, and Japan.
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $13.48 | $12.82 | -4.90% |
Jul 24, 2025 | $16.51 | $12.54 | -24.05% |
Apr 24, 2025 | $17.77 | $18.55 | +4.39% |
Feb 27, 2025 | $21.96 | $19.23 | -12.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NovoCure Ltd (NVCR) report earnings?
NovoCure Ltd (NVCR) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).
What is NovoCure Ltd (NVCR) earnings time?
NovoCure Ltd (NVCR) earnings time is at Feb 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2025 (Q4) is -0.4.